Haleon (LON:HLN) Receives “Buy” Rating from Jefferies Financial Group

Haleon (LON:HLN)‘s stock had its “buy” rating restated by equities research analysts at Jefferies Financial Group in a note issued to investors on Wednesday,Digital Look reports. They presently have a GBX 450 price target on the stock. Jefferies Financial Group’s target price would suggest a potential upside of 18.81% from the stock’s current price.

Several other brokerages also recently issued reports on HLN. Berenberg Bank upped their price objective on shares of Haleon from GBX 507 to GBX 517 and gave the company a “buy” rating in a research note on Wednesday, November 5th. Royal Bank Of Canada restated a “sector perform” rating and set a GBX 370 price objective on shares of Haleon in a research note on Friday, October 31st. Finally, JPMorgan Chase & Co. increased their target price on shares of Haleon from GBX 315 to GBX 335 and gave the company an “underweight” rating in a research note on Wednesday, November 26th. Three equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average target price of GBX 422.40.

Haleon Stock Performance

HLN stock traded up GBX 5.87 during trading on Wednesday, hitting GBX 378.77. The company had a trading volume of 2,147,000,000 shares, compared to its average volume of 233,706,406. The company has a quick ratio of 0.93, a current ratio of 0.84 and a debt-to-equity ratio of 53.36. The firm has a 50-day moving average price of GBX 368.51 and a 200-day moving average price of GBX 359.05. The firm has a market cap of £33.73 billion, a PE ratio of 22.68, a price-to-earnings-growth ratio of 1.49 and a beta of 0.19. Haleon has a 1-year low of GBX 325.10 and a 1-year high of GBX 419.50.

About Haleon

Haleon (LSE / NYSE: HLN) is a world-leading consumer health company, with a clear purpose to deliver better everyday health with humanity. In July 2022, it listed as an independent company on the London and New York Stock Exchanges.

Haleon’s product portfolio spans six major categories – Oral Health, Vitamins, Minerals and Supplements (VMS), Pain Relief, Respiratory Health, Digestive Health and Therapeutic Skin Health and Other. Its long-standing brands – such as Advil, Centrum, Otrivin, Panadol, parodontax, Polident, Sensodyne, Theraflu and Voltaren – are built on trusted science, innovation and deep human understanding.